Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Bimekizumab Reduces Uveitis Incidence in axSpA Patients
The study led by Matthew A. Brown, Genomics England, London, United Kingdom, and Martin Rudwaleit, Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany. Patients with axial spondyloarthritis (axSpA) treated with bimekizumab exhibited a markedly lower incidence of uveitis compared to those receiving…
Ocular Side Effects Linked to Ovarian Cancer Drug
A recent study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago has identified significant ocular side effects associated with mirvetuximab soravtansine (Elahere), a drug approved for ovarian cancer treatment. The research, conducted by Stanford University, highlights the…
ANX007 Protects Vision in Dry AMD – AAO 2024
A new investigational drug, ANX007, offers hope for the millions of people suffering from geographic atrophy, a severe form of dry age-related macular degeneration (AMD). The drug’s potential to reduce vision loss and protect essential retinal structures was highlighted at…
Long-Term Antiviral Therapy for Ocular Shingles
A new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania and the NYU Grossman School of Medicine suggests that taking an antiviral medication for a year can help prevent vision loss caused by…
OSA 2024 Winners Highlight Innovations in Ophthalmology
VSY Biotechnology GmbH, a global leader in ophthalmic innovation and research, handed the prestigious Ophthalmology Star Awards 2024 (OSA) to its owners during the Satellite Symposium at the ESCRS 2024 Congress in Barcelona. The awards, which were personally presented to…
New Drug Targets for Inherited Retinal Diseases Identified
An international team of researchers has discovered new drug targets for inherited retinal diseases, such as retinitis pigmentosa (RP). Using advanced proteomics, they identified common critical pathways in different disease models, offering hope for broad-spectrum treatments. Key Findings in Retinitis…
Ophthalmic Drug Delivery Summit 2024
In January, over 60 world-renowned experts in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit. This industry-focused event aims to advance effectiveness, durability, and minimally invasive techniques in retinal drug delivery. Key…
Reducing the Carbon Footprint of Intravitreal Injections
Adopting specific treatment protocols, minimizing travel for patients and staff, and reducing unnecessary use of personal protective equipment (PPE) can significantly decrease the carbon footprint of intravitreal injections. This topic was discussed in detail by Redmer van Leeuwen, MD, PhD,…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…